Ipilimumab Improves Overall Survival in Previously Treated, Advanced Melanoma Patients with Good and Poor Prognostic Factors

被引：0
|
作者：
O'Day, Steven J. [1 ,2 ]
McDermott, David F. [10 ]
Urba, Walter J. [4 ]
Wolchok, Jedd D. [5 ]
Robert, Caroline [6 ]
Haanen, John B. [7 ]
Dummer, Reinhard [8 ]
Messina, Marianne [9 ]
Hoos, Axel [9 ]
Hodi, F. Stephen [3 ]
机构：
[1] Angeles Clin, Los Angeles, CA USA
[2] Res Inst, Los Angeles, CA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Earle A Chiles Res Inst, Portland, OR USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] Inst Gustave Roussy, Villejuif, France
[7] Netherlands Canc Inst, Amsterdam, Netherlands
[8] Univ Hosp, Zurich, Switzerland
[9] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[10] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
来源：
JOURNAL OF IMMUNOTHERAPY | 2010年 / 33卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：905 / 906
页数：2
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MELANOMA PREVIOUSLY TREATED WITH IPILIMUMAB IN PORTUGAL
    Silva Miguel, L.
    Vargas Lopes, F.
    Pinheiro, B.
    Wang, J.
    Xu, R.
    Pellissier, J.
    Laires, P. A.
    VALUE IN HEALTH, 2016, 19 (07) : A730 - A730
  • [22] Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
    Koguchi, Yoshinobu
    Hoen, Helena M.
    Bambina, Shelly A.
    Rynning, Michael D.
    Fuerstenberg, Richard K.
    Curti, Brendan D.
    Urba, Walter J.
    Milburn, Christina
    Bahjat, Frances Rena
    Korman, Alan J.
    Bahjat, Keith S.
    CANCER RESEARCH, 2015, 75 (23) : 5084 - 5092
  • [23] Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
    Reinhard Dummer
    Dirk Schadendorf
    Paolo A Ascierto
    James Larkin
    Celeste Lebbé
    Axel Hauschild
    Journal of Translational Medicine, 12 (Suppl 1)
  • [24] Two year overall survival rate of all advanced melanoma patients treated with ipilimumab in Australia 2013-2014
    Kim, H.
    Comey, S.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S4 - S4
  • [25] Comments on "Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study"
    Yilmaz, Melek Tugce
    Elmali, Aysenur
    Yazici, Gozde
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (08) : 2060 - 2062
  • [26] OVERALL SURVIVAL WITH NIVOLUMAB FOR PATIENTS WITH ADVANCED, PREVIOUSLY TREATED RENAL CELL CARCINOMA
    Sullivan, W.
    Lee, D.
    Willis, A.
    Doan, J.
    Gooden, K.
    Sowdani, A.
    VALUE IN HEALTH, 2017, 20 (05) : A96 - A96
  • [27] FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab
    Iravani, Amir
    Wallace, Roslyn
    Lo, Serigne N.
    Galligan, Anna
    Weppler, Alison M.
    Hicks, Rodney J.
    Sandhu, Shahneen
    RADIOLOGY, 2023, 307 (03)
  • [28] Association between tumor shrinkage and overall survival in advanced melanoma patients with nivolumab in combination with ipilimumab
    Feng, Yan
    Gupta, Manish
    Agrawal, Shruti
    Roy, Amit
    CANCER RESEARCH, 2015, 75
  • [29] Prognostic factors for survival of patients treated systemically for disseminated melanoma
    Eton, O
    Legha, SS
    Moon, TE
    Buzaid, AC
    Papadopoulos, NE
    Plager, C
    Burgess, AM
    Bedikian, AY
    Ring, S
    Dong, Q
    Glassman, AB
    Balch, CM
    Benjamin, RS
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) : 1103 - 1111
  • [30] LONG-TERM SURVIVAL OF PATIENTS WITH ADVANCED MELANOMA TREATED SECOND LINE WITH IPILIMUMAB
    Lee, D.
    Pericleous, L.
    Lebmeier, M.
    Winn, B.
    Batty, A.
    Nikoglou, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 370 - 370
12345